KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Gross Margin (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Gross Margin for 7 consecutive years, with 83.88% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 119.0% year-over-year to 83.88%, compared with a TTM value of 81.77% through Dec 2025, down 460.0%, and an annual FY2025 reading of 81.77%, down 460.0% over the prior year.
  • Gross Margin was 83.88% for Q4 2025 at Alnylam Pharmaceuticals, roughly flat from 84.21% in the prior quarter.
  • Across five years, Gross Margin topped out at 89.8% in Q2 2024 and bottomed at 133.94% in Q1 2025.
  • Average Gross Margin over 5 years is 74.45%, with a median of 85.61% recorded in 2021.
  • The sharpest move saw Gross Margin surged 1344bps in 2024, then plummeted -22290bps in 2025.
  • Year by year, Gross Margin stood at 86.99% in 2021, then dropped by -1bps to 86.22% in 2022, then dropped by -3bps to 83.63% in 2023, then dropped by -1bps to 82.69% in 2024, then grew by 1bps to 83.88% in 2025.
  • Business Quant data shows Gross Margin for ALNY at 83.88% in Q4 2025, 84.21% in Q3 2025, and 81.64% in Q2 2025.